Our patient’s survival of more than three years is more than the median overall survival of patients with glioblastoma and methylated MGMT promotor with standard therapy, ranging from 21.7 up to more than 30 months [26,27,28], mostly due to a better response to alkylating chemotherapy. The gene discussed is MGMT; the disease is glioblastoma.